Ipsen (XPAR:IPN) Valuation Rank


XPAR:IPN Ipsen SA XPAR:IPN
96 GF Score
Price €162.70
GF Value €134.33
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Ipsen Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Ipsen Valuation Rank Related Terms

XPAR:IPN
96GF Score
Ipsen SA XPAR:IPN
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ipsen (XPAR:IPN) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of €162.70 is trading 21.1% above its estimated GF Value™ of €134.33. GuruFocus considers Ipsen to be Modestly Overvalued.

Key valuation signals for XPAR:IPN:

  • Valuation Rank:
  • GF Value™: €134.33 vs. price of €162.70 (21.1% above fair value)
  • GF Score™: 96/100 with 7 warning signs

No single metric tells the full story. See the XPAR:IPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
96GF Score

Get the complete analysis for XPAR:IPN

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€162.70
Price
€134.33
GF Value